收藏切换
Advances in drugs on targeting SMN2 for the treatment of spinal muscular atrophy
收藏切换
PDF
Zhi-hao HE, Xiang ZHANG*
Acta Pharmaceutica Sinica | 2022, 57(5) : 1301 - 1311
Less
收藏切换
Acta Pharmaceutica Sinica | 2022, 57(5): 1301-1311
Reviews
Advances in drugs on targeting SMN2 for the treatment of spinal muscular atrophy
Full
Zhi-hao HE, Xiang ZHANG*
Affiliations
  • Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Published: 2022-05-12 doi: 10.16438/j.0513-4870.2022-0062
Outline
收藏切换

As one of the most serious hereditary neuromuscular disease, spinal muscular atrophy (SMA) is caused by the loss or mutation of survival motor neuron 1 (SMN1) gene. It leads to a decrease in the level of SMN protein and a consequent loss of alpha neurons and progressive muscle atrophy resulting in the progressive muscle weakness, the significant disability and the shortened lifespan. Up till now, only three drugs have been approved for SMA, including the gene therapy drug onasemnogene abeparvovec. The antisense oligonucleotide drug nusinersen and and the small molecule chemical drug risdiplam were briefly introduced. Some representative samples of the small molecule chemical drugs and antisense oligonucleotide drugs targeting SMN2 in the clinical trial or preclinical research phases were also reviewed.

spinal muscular atrophy  /  nusinersen  /  risdiplam  /  antisense oligonucleotides
Zhi-hao HE, Xiang ZHANG. Advances in drugs on targeting SMN2 for the treatment of spinal muscular atrophy[J]. Acta Pharmaceutica Sinica, 2022 , 57 (5) : 1301 -1311 . DOI: 10.16438/j.0513-4870.2022-0062
Year 2022 volume 57 Issue 5
PDF
184
70
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2022-0062
  • Receive Date:2022-01-14
  • Online Date:2025-12-23
  • Published:2022-05-12
Article Data
Affiliations
History
  • Received:2022-01-14
  • Revised:2022-02-23
Funding
Affiliations
    Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2022-0062
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT